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Cells of the immune system interact with each other or with specific antigen in the 
context of molecules controlled by the human HLA-D/DR region (1-3). For example, 
HLA-D/DR  region-encoded molecules regulate immune responsiveness by acting as 
restriction elements in the proliferative responses of T  lymphocytes to antigens (3) or 
by serving as target antigens for alloreactive T  cell killing (4).  10 alleles of the HLA- 
DR locus have been identified and the presence of certain of these alleles  has been 
associated with susceptibility to a  number of human diseases.  Included in this group 
of diseases  are  many conditions  that  have  aberrant  immunological processes  as  a 
major  component,  such  as  multiple  sclerosis,  systemic  lupus  erythematosus,  and 
rheumatoid  arthritis  (5).  A  comprehensive  understanding  of the  structure  of the 
molecules encoded by the  HLA-D/DR  region could provide valuable  insights  into 
both the basic mechanisms underlying normal immune regulation,  and  the role of 
these antigens in disease association. 
The  HLA-D  region-encoded  glycoproteins  are  composed  of two  noncovalently 
associated chains of 34,000 tool wt (alpha chain) and 29,000 mol wt (beta chain) and, 
in this respect, are similar to the murine Ia (immune response-associated)  antigens. 
The identification and characterization of two distinct Ia molecules encoded by the 
I-A  and I-E subregions in mice (6)  and the association of specific immune responses 
with  molecules encoded by each of these  loci has  prompted the  search  for similar 
alloantigens  in  man.  The  predominant  family of human  Ia  molecules,  known  as 
HLA-DR, has been shown to be homologous to the murine I-E subregion molecules 
on the basis of amino acid sequence analysis (7). Evidence now suggests that rather 
than existing as  a  single species,  HLA-DR represents  a  family of molecules that  is 
distinguished by several structurally distinct beta chains (8, 9). A second homologue 
of the murine I-E antigens, known as SB, has recently been described in humans (10). 
This set of antigens, controlled by a  subregion separate from the DR subregion  (11), 
has been  demonstrated by amino-terminal amino acid sequence analysis to be I-E- 
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like but,  nevertheless, distinct  from  HLA-DR  (12).  In  addition to  these  I-E-related 
molecules, a human equivalent of the murine I-A molecule has recently been described 
and designated HLA-DS for "second D  region locus" (13). 
The  already complex HLA-DR  alloantigen system  has  been  complicated further 
by the description of at least four additional HLA-linked series of B cell alloantigens, 
MB, MT, Te, and DC  (14-17).  These specificities were invoked to explain reactivity 
patterns of some alloantisera that did not correlate with known HLA-DR alleles but 
instead included two or more of the HLA-DR alleles. It is not clear if these "supertypic 
specificities"  represent  shared  (public)  determinants  on  the  associated  HLA-DR 
molecules (18) or if they represent specificities present on molecules distinct from DR 
(17).  Recent evidence indicates that  at least one of the supertypic specificities, DC1, 
may be present on the HLA-DS family of molecules. By amino acid sequence analysis, 
the alpha chain of the molecule carrying this specificity is homologous to the alpha 
chain of the HLA-DS molecule (19). 
The present study describes the use of monoclonal antibody IVD 12 for the isolation 
and partial structural characterization of a  molecule present primarily on human  B 
cells having DR4 or DR5 phenotypes. This molecule was purified from a  DR4/4  cell 
line by adsorption on IVD 12 and was shown by amino-terminal amino acid sequence 
analysis to be distinct from the HLA-DR  molecules isolated from the same cell line. 
Furthermore, the IVD12-reactive molecule was found to be homologous to the murine 
I-A and  human  HLA-DS  molecules.  The  pattern  of binding obtained  by  indirect 
fluorescent staining and  direct  cellular binding with  IVD12  is strikingly similar to 
that  pattern  obtained  using  alloantisera  against  the  MB3  specificity  (20).  These 
findings suggest that  the IVD12-reactive molecules not  only represent a  human  I-A 
equivalent but also bear the MB3 specificity. 
Materials  and  Methods 
Monoclonal Antibodies.  Monoclonal antibody IVD 12 was the result of a fusion between spleen 
cells from mice immunized with the human B cell line PRIESS (21)  (DR4/4)  and the mouse 
hybridoma line SP2/0-Ag-14 (22).  8-10-wk-old BALB/c mice were immunized intraperitone- 
all~z with  10  7 intact cells once a week for 3 wk. 33 d after the last injection, the mice were given 
10  cells intravenously, and the fusion was performed 3 d  later as described by Kennett et al. 
(23).  The antibody IVD12 is a yl~, as determined by Ouchterlony analysis. The monoclonal 
antibodies L203, L227, IIIE3, and I-LR1 have been described (9,  12, 24). 
Immunoglobulins used  for  affinity columns  were  isolated from  ascites using  ammonium 
sulfate at 50% saturation. After dialysis, preparations were coupled to Sepharose 4B (Pharmacia 
Fine Chemicals, Piscataway, N  J)  (25).  Spent  culture media containing the  antibodies were 
concentrated 5-10 times and used directly for immunoprecipitations. 
Normal B Cell Panel  Peripheral blood B ceils from 75 unrelated members of the tissue-typing 
laboratory reference panel were screened by indirect immunofluorescence (26) for the presence 
of IVD12-reactive cell surface  antigens.  Reactivity with  IVD12  or the control monoclonal 
antibodies was determined by counting positive cells using epifluorescence optics. The HLA- 
DR  phenotype  of the  cells used  in  the  B  cell  panel  had  been  previously determined  by 
microcytotoxicity using  typing  reagents  from  the  Eighth  International  Histocompatibility 
Workshop, as well as local alloantisera. Likewise, B cells from three informative families were 
examined by fluorescence for their ability to bind IVD12. 
B Lymphoblastoid Cell Lines.  HLA-DR homozygous cell lines were used in the cellular binding 
assays. The ability of IVD12 to bind the cell lines was examined using the method of Williams 
(27).  Briefly, individual wells of polyvinyl microtiter plates were coated with glutaraldehyde- 
fixed human B cell lines at a concentration of 5 X l0  b cells per well. 50 ~1 of culture supernatant 
containing IVD12  or a  1:100  dilution of ascites containing IVD12  was added to each well. GILES ET  AL.  1463 
After  a  1-h  incubation,  the  microtiter plates were  washed  and  1-1.5  ×  104  cpm  of 125I- 
radiolabeled affinity-purified rabbit anti-mouse immunoglobulin (Cappel Laboratories, Coch- 
ranville, PA) was added to each well. After a  3-h incubation, the plates were washed and the 
radioactivity in  each  well was  measured.  Alternatively, cellular binding was  measured  by 
indirect immunofluorescence. The cell line PRIESS was used for isolation and purification of 
IVD12-reactive molecules for structural analysis. 
Isolation  of Radiolabeled  Antigens.  PRIESS cells were radiolabeled in culture with [all]amino 
acids, lysed with 0.5% Nonidet P-40 (NP-40) 1, and passed over a lentil-lectin-coupled  Sepharose 
column to isolate a  glycoprotein pool as previously described (9). Glycoprotein pools isolated 
from i-3 ×  10  a PRIESS ceils were first depleted of DR antigens by two passages over a  10-ml 
anti-DR affinity column containing three anti-DR monoclonal antibodies, L203, L227,  and 
IIIE3 (9). In one experiment, the DR-depleted glycoprotein pool was chromatographed on a 6- 
ml  anti-SB  affinity column  containing the  monoclonal  antibody I-LR1  (12).  The  DR-SB- 
depleted glycoprotein pool was then chromatographed on a  10-ml IVD12 immunoadsorbent, 
and the adherent  antigens were eluted with  1.5 M  ammonium  thiocyanate in Tris-buffered 
saline (TBS) (0.01 M  Tris, 0.15 M  NaC1, pH 7.5). HLA-DR antigens were isolated by passage 
over a IIIE3 antibody affinity column. Pools of eluted antigens were dialyzed against TBS and 
the antigens were recovered by precipitation with ten volumes of cold acetone. 
For some experiments, radiolabeled antigens were isolated by immunoprecipitation. In these 
experiments, radiolabeled immunoglobulin was removed by preclearing the glycoprotein pool 
with protein A-bearing Staphylococcus aureus cells (Pansorbin, Calbiochem, San Diego, CA) (28), 
which had been extensively prewashed with TBS containing 0.25%  NP40 and 0.1% SDS. The 
immunoglobulin-depleted pool was then incubated with monoclonal antibody IVD12 for  15 
rain at 370C and overnight at 4°C. Rabbit anti-mouse immunoglobulin was then added and 
the same incubation protocol was followed. The complexes were removed by centrifugation, 
then washed with TBS containing 0.25%  NP-40 followed by TBS without NP-40. 
SDS-Polyac~ylamide  Gel Electrophoresis.  IVD12- and IIIE3-reactive radiolabeled antigens pu- 
rified by either affinity chromatography or immunoprecipitation were electrophoresed under 
reducing conditions on  12.5% SDS-polyacrylamide tube gels (29).  The gels were fractionated 
into 0.05%  SDS in water, and 50-/~1 aliquots of each sample were counted to determine the 
positions of the alpha and beta polypeptides. Appropriate fractions were pooled and dialyzed 
against distilled water before amino acid sequence analysis. 
Amino  Acid  Sequence Determination.  Isolated alpha  and  beta chains  labeled with  a  single 
[3H]amino acid were sequenced on a Beckman 890C sequencer (Beckman Instruments, Fuller- 
ton, CA) as previously described (9). Butyl chloride fractions were evaporated using a stream 
of N2, scintillation fluid was added to each fraction, and the radioactivity in each fraction was 
determined using a liquid scintillation counter. 
Results 
Monoclonal Antibody IVD12 is Directed against a Specificity Encoded by a Gene Closely Linked 
to HLA-DR4  and HLA-DR5  Loci.  The allospecificity of antibody IVD12 was deter- 
mined by testing against a  panel of B  cells from  75 normal unrelated donors  (Table 
I). Antibody IVD 12 reacted with the ceils of all 20 DR4-positive individuals and with 
14  of 16  DR5-positive donors, giving a  correlation of 0.81  with these two  antigens. 
IVD12  was also found to react with B  cells from three other individuals other than 
these positive DR4  and DR5  donors. Two of these individuals were typed as DRw6 
and the third was typed as DRw9.  Additional information regarding the specificity 
of antibody IVD12  was  obtained when  IVD12  was  used  in cellular binding assays 
with 19 human lymphoblastoid cell lines homozygous for HLA-DR  (Table II). IVDI2 
reacted with all four of the cell lines that were DR4-positive and two of three lines 
that  were  DR5-positive.  All other  cell  lines were  negative.  This  reactivity pattern 
1 Abbreviations used in this paper: NP-40, Nonidet P-40; SDS, sodium dodecgl sulfate; TBS, Tris-buffered 
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TABLE  I 
Correlation Between IVD12 Reactivity and HLA-DR Phenotype  on B Cells 
from a Panel of 75 Unrelated Donors 
HLA-DR pheno- 
type 
IVD 12 reactivity/presence of DR phenotype 
+/+  +/-  -/+  -/-  X  2  r 
DR 1  3  32  7  33  0.63  -0.09 
DR2  9  26  16  24  1.13  -0.12 
DR3  6  29  8  21  0.00  0.00 
DR4  20  15  0  40  28.32  0.61 
DR5  14  21  2  38  11.62  0.39 
DRw6  5  30  9  31  0.38  -0.07 
DR7  1  34  16  24  12.65  -0.41 
DRw8  2  18  3  22  0.07  -0.03 
DRw9  1  19  3  22  0.08  -0.04 
DRwl0  0  20  2  23  0.32  -0.08 
DR4 +  DR5  31  4  2  38  49.57  0.81 
* X  2 with  Yates'  correction;  r  values were  obtained  using the  formula  r  = 
and positive or negative correlation by the formula ad =  bc. 
TABLE  II 
Reactivity of lVD12 with Human B Lymphoblastoid Cell Lines Homozygous 
for HLA-DR 
IVD 12 reac-  DR genotype  Cell lines  tivity 
1/1  3104, 3099, HOM2  - 
2/2  3161, 3107, KCAR  - 
3/3  Mat3, Hal 
4/4  3103, 3164, WALK, PRIESS  + 
5/5  Sweig, 3105  + 
3106 
w6/w6  Daudi,* Eld2 
7/7  3163, New7 
* The Daudi cell line may be DRw6/-. 
obtained  with IVD12  indicates that  this monoclonal  antibody  is directed  against  an 
antigen  encoded  by a  gene closely linked to the genes encoding  DR4  and  DR5. 
Monoclonal  Antibody IVD12 Reactivity Segregates with HLA Haplotypes Positive for DR4 or 
DR5.  Segregation  of the  IV12-reactive  determinant  with  DR4  and  DR5  was  ob- 
served in three families, as shown  in Table  III. The  mother  of one of the families was 
positive for DR5  but negative for IVD12  reactivity. All other DR4  or DR5  individuals 
were positive with IVD 12. These data substantiate the segregation of IVD 12 reactivity 
with DR4  and/or  DR5. 
Monoclonal Antibody IVD12 Recognizes an Ia-like Molecule  Distinct from HLA-DR.  After 
passage over an anti-DR  and  an anti-SB affinity column,  the reactive antigens  from 
a  [aH]leucine-labeled  PRIESS  (DR4/4)  glycoprotein  pool  were  isolated  using  a 
column  containing  IVD12.  These  IVD12-purified  antigens  were  shown  to  be  a 
bimolecular  complex  that migrated  under  reducing  conditions in a  molecular  weight 
range similar to that  of Ia antigens  (i.e.,  ~34,000  for the alpha  chain  and  29,000  for 
the  beta  chain)  on  a  12.5%  polyacrylamide  gel  (Fig.  1).  Since  these IVD12-reactive GILES  ET  AL.  1465 
TASTE III 
Segregation of lVD12 Reactivity with HLA Haplotypes in Three Informative Families 
Fam-  Father  Mother 
ily 
Children 
1  2  3  4 
Gom  Ib  Aw24, Bw44, Cw5, DR2  Cd  Aw24, Bw35, Cw4, DR5  ~]  An  ~-c]  N° 
Aw31~ Bw38~ Cw-~ DR4  A3~ Bw57~ Cw-~ DR7  a/d  a/d 
b  A1, Bw57, Cw-, DR7  A2~ Bw62, Cw3, DR4  a/c 
b  Aw23, Bwl9, Cw-, DR4  d  Aw32,  Bw51, Cw-, DR5  bl.b_~  b~  b  ~  a/c 
Boxes indicate reactivity with IVD 12 by immunofluorescence. 
* Not tested for IVD12 reactivity. 
".VDI 2 
'o 6~- 
X  / 
0  Froction Number 
Fxo.  1.  SDS-polyacrylamide  gel  electrophoresis  under  reducing  conditions  of  IVD12-reactive 
antigens isolated from the cell line PRIESS. Migration was from left to right. Arrows indicate the 
positions of immunoglobulin heavy and light chain markers. 
molecules were not substantially removed from a  glycoprotein pool with a  series of 
antibodies known to be directed to HLA-DR or HLA-SB specificities, the data suggest 
that  the Ia molecules reactive with IVD12 are separate and distinct  from HLA-DR 
or HLA-SB molecules. 
Monoclonal Antibody IVD12-reactive  Alpha and Beta Chains Are Homologous to Murine I-A 
and Human HLA-DS by Amino Acid Sequence Analysis.  PRIESS cells were radiolabeled 
with  [aH]isoleucine,  [aH]leucine,  [aH]phenylalanine,  [aH]tyrosine,  and  [aH]valine, 
independently.  Alpha and beta chains were isolated from the IVD12-reactive prepa- 
rations  and  their  amino-terminal  amino  acid  sequences  were  determined.  These 
sequences were compared with sequences from murine I-E (30),  DR  (12),  I-A (30), 
and  DS  (13)  molecules  (Table  IV).  The  DR  sequence  was  obtained  using  IIIE3- 
reactive  molecules  isolated  from  the  cell  line  PRIESS.  Obvious  differences  were 
demonstrated when the amino acid sequences of IVD12-reactive alpha chains were 
compared with murine I-E alpha chains and human DR alpha chains.  Using the 5 
radiolabeled amino acids, 18 differences were found between DR and IVD 12-reactive 
alpha chains  within  the  first  29  amino acids.  When  the  sequence  obtained  for DS 
alpha chains was compared with the IVD 12-reactive alpha chain sequence, however, 
no differences were observed. Only six differences were demonstrated between IVD 12- 
reactive and I-A alpha chains.  These data indicate that  alpha chains  isolated  from 
IVD12-reactive molecules are quite different from rnurine I-E and human HLA-DR 
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TABLE  IV 
Amino Acid Sequence Comparison of L E-,* DR-,:~ I-A-,*  DS-,§ and IVD l 2-Reactive Antigens 
Part A:  Alpha Chains 
Position:  1  3  4  6  7  8  11  12  13  14  15  16  19  22  24  25  26  29 
I-E  I  -[I  I  I  F  Y  L  L  V  F  V 
DR  I  V  I  I  F  Y  L  F  F  F 
I-A  I  V  V  Y  V  Y  I  .¶  Y 
DS  I  V  V  Y  V  L  Y  Y 
IVD 12-reactive  I  V  V  Y  V  L  Y  Y  Y  F 
Part B:  Beta Chains 
Position:  7  8  9  10  11  14  16  17  18  24  26  27  30  31  32 
I-E  F  L  Y  V  L  F  Y  V  F  L  F 
DR  F  L  F  F  Y  Y 
I-A  F  V  Y  F  F  Y  F  I  Y  Y 
DS  F  V  F  Y  F 
IVD 12-reactive  F  V  Y  F  Y  F  V  V  Y  Y 
* I-E alpha and beta and I-A alpha and beta composite (30). 
IIIE3-reactive molecules from PRIESS. 
§ DS from reference 13. 
II Absence of particular  amino acid(s) found in corresponding chains of other molecules. 
¶ Not determined. 
Comparison  of  the  sequences  of  DR  and  IVD12-reactive  beta  chains  revealed 
several differences. Using the 5  radiolabeled amino acids, eight  differences could be 
demonstrated  in  the  first  32  amino  acids.  Although  only  limited  information  is 
available on  the  DS beta  chain  sequence, a  comparison of the IVD12-reactive beta 
chain  sequence  with  this  partial  sequence  demonstrated  only  minor  differences 
between the two chains.  As with the alpha chains, beta chains isolated from IVD12- 
reactive molecules are considerably different from murine I-E and human  HLA-DR 
beta  chains,  but  exhibit  striking  homology with  murine  I-A  and  human  DS  beta 
chains. 
Discussion 
This study  describes the isolation and partial structural  characterization of an  Ia- 
like molecule present on human B cells or B cell lines that generally display the DR4 
and/or  DR5  phenotypes.  Using the  monoclonal antibody  IVD12,  this molecule has 
been specifically purified from a DR4 homozygous cell line and has been demonstrated 
by  amino-terminal amino acid sequence analysis of both  chains  to be distinct  from 
HLA-DR  molecules but  homologous to the murine I-A and  human  HLA-DS mole- 
cules. 
The strong association of the IVD12 specificity with both DR4 and DR5, as shown 
in  Tables  I-III,  suggests  that  the  IVD12-reactive  molecules  also  bear  the  MB3 
specificity described  by  Duquesnoy  and  Marrari  (20).  Complete  inclusion  of DR4 
(i.e.,  all  20  DR4  were  IVD12  positive)  and  high  frequency of reactivity with  DR5- 
bearing cells  (i.e.,  14 of 16  DR5 were IVD12 positive), as well as  the reactivity with 
some cells having DRw6 or DRw9 specificities, correlates well with findings obtained 
using MB3 allosera defined in the Eighth International Histocompatibility Workshop 
(20).  Alternatively, the IVD 12-reactive molecule could be controlled by genes closely GILES ET AL.  1467 
linked to MB3. Comparison of IVD12-reactive products with products reactive with 
MB3 alloantisera are in progress. 
Results  from  studies  in  which  IVD12  reactivity  was  followed  in  three  families 
indicate that IVD12 reacts with a determinant encoded within the HLA chromosomal 
region. In each case the haplotypes positive for IVD12 were also positive for DR4 or 
DR5.  In family Nia,  the  mother was typed as HLA-DR5  but was not  positive for 
IVD12. Unfortunately, separate segregation of this haplotype could not be observed 
because the two children  that received the DR5 haplotype also had a  DR4-positive, 
IVD12-positive haplotype from the father. 
Biochemical analysis of the IVD 12-reactive antigens revealed that both the alpha 
and beta chains from these molecules are distinct from HLA-DR but homologous to 
the murine I-A molecules rather than the I-E molecules. Likewise, the alpha and beta 
chains are homologous to the DS molecule (13). With the 5 radiolabeled amino acids 
used in this study, no differences were observed in the first 20 amino acids when the 
IVD12-reactive alpha chain from a DR4 line was compared with the DS alpha chain 
from a DR7 cell line (13).  Variation between the IVD12-reactive and DS beta chains 
is seen at position 9, where a  tyrosine is found in the IVD12-reactive beta chain that 
is absent  in  the DS beta chain.  While  the  data  are limited,  this kind  of structural 
variation among beta chains and not alpha chains is typical for class II gene products 
of both humans and mice (31, 32). Although additional sequence data are needed to 
determine  the  extent  of variation  among  both  alpha  and  beta  chains  of IVD12- 
reactive and DS molecules, these data are consistent with  the hypothesis that  these 
two Ia molecules are, in  fact, encoded  by the same alpha and  beta chain  loci, and 
that the variation observed between the beta chains is due to allelic polymorphism of 
the locus. Furthermore, amino acid sequence homology of the HLA-DS alpha chain 
with the DC1  alpha chain  (19)  suggests that  all of these molecules, DS,  DC1,  and 
now MB3, are aUelic products of a single gene. 
This description of a  molecule that is homologous to murine I-A is consistent with 
recent evidence suggesting the presence of multiple loci within the HLA-D region (13, 
17,  19,  33-37).  Previous  studies  from  this  laboratory  using  the  cell  line  PRIESS, 
coupled  with  the  present  study,  have now structurally  characterized  three  distinct 
HLA-D region encoded molecules from the same cell line, DR, SB, and MB/DS. All 
three molecules have structurally distinct alpha and beta chains. DR and SB are I-E- 
like and MB/DS is I-A-like. 
Although a number of studies suggest that the supertypic specificities, such as MB, 
may be present on the same molecule as the HLA-DR specificities (18, 38), this study 
supports the view that at least some supertypic specificities are found on molecules 
encoded  by  loci  separate  and  distinct  from  those  loci  which  encode  HLA-DR 
molecules. More evidence obtained with monoclonal antibodies and homozygous cell 
lines is needed to determine if other supertypic specificities (MT, Te, etc.) represent 
molecules  encoded  by even additional  loci  or  if they are determinants  present  on 
molecules already described. 
If further findings support  the assignment of IVD12 as an anti-MB3  monoclonal 
antibody, this antibody should be invaluable for the precise characterization of these 
HLA-D region products and for studying their tissue distribution,  functional signifi- 
cance, and role in disease association.  Preliminary experiments (G. Nunez, R. Giles, 
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that IVD 12-reactive molecules are expressed on all DR-positive cells with one notable 
exception. Although a  large percentage of peripheral blood monocytes appear to be 
reactive with  antibodies  against  DR antigens,  only a  small  subpopulation  of these 
cells  is  reactive  with  IVD12.  Experiments  to  determine  whether  the  expression  of 
MB/DS molecules on monocytes and macrophages can be modulated, and whether 
these determinants  stimulate  allogeneic T  cells  and serve as restriction elements for 
antigen-dependent T  cell proliferation are currently in progress. In addition, recent 
findings demonstrating strong association of IVD 12 reactivity in patients with chronic 
lymphocytic leukemia  (39,  40)  provide  a  potentially  rewarding  approach  for  the 
analysis of the structural basis of disease association at the molecular level. 
Summary 
Monoclonal  antibody  IVD12  was  used  to  isolate  and  characterize  a  human  Ia 
molecule present  on B  cells  that  generally  display  DR4  or  DR5  phenotypes.  The 
specificity of binding of IVD12 to human peripheral  blood B cells  from  75 normal 
individuals and  19 homozygous human lymphoblastoid B cell lines was identical to 
the  supertypic  specificity  MB3  previously  defined.  Furthermore,  IVD12-reactivity 
was  shown  to  segregate  with  HLA in  three  informative  families.  In  each  family, 
individuals  positive for IVD12 binding were  also positive  for DR4 or DR5.  Using 
IVD12, a molecule has been isolated from the homozygous cell line PRIESS (DR4/4) 
and has been shown by amino acid sequence analysis to be homologous to the murine 
I-A and human HLA-DS molecules. These findings suggest that the MB3 specificity 
is found on a  molecule encoded by loci distinct from those loci which encode HLA- 
DR molecules. 
This molecule represents the third family of HLA-D region molecules isolated from 
the cell line PRIESS. Both HLA-DR and HLA-SB molecules from this cell line were 
previously shown by amino acid sequence analysis to be I-E-like but distinct from one 
another. Collectively, these data provide evidence that the HLA-D region contains at 
least six loci encoding distinct alpha and beta chains for the HLA-SB, HLA-DR, and 
HLA-DS molecules. 
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